Prelude Therapeutics announced preclinical data for PRT13722, a first-in-class KAT6A degrader for HR+/HER2- breast cancer, to be presented at AACR 2026, with IND filing on track for mid-2026.
Key takeaways
PRT13722 drives durable complete tumor regressions as monotherapy in HR+/HER2- xenograft models at well-tolerated doses.
PRT13722 shows synergy with ET, CDK4/6 inhibitors, and PI3Kα inhibitors in HR+ BC models, including therapy-resistant cells.
PRT13722 has improved preclinical hematological safety vs prifetrastat, enabling potential combinations.
IND filing for PRT13722 planned mid-2026, Phase 1 initiation anticipated 2H 2026.
Presentation at AACR Annual Meeting 2026 on April 20, 2026.